Rankings
▼
Calendar
▼
CURX Q4 2023 Earnings Report — Curanex Pharmaceuticals Inc Common Stock Revenue & Financial Results | Market Cap Arena
Curanex Pharmaceuticals Inc Common Stock
CURX
Q4 2023 Earnings
Reported December 30, 2023
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Metric
Q4 2023
Q3 2023
Q4 2022
QoQ Change
YoY Change
Revenue
$0
—
—
—
—
Op. Income
-$12.7K
—
—
—
—
EPS (Diluted)
$-0.00
—
—
—
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$0
Selling & Marketing
$0
General & Administrative
$0
SG&A Expenses
$12.7K
Other Expenses
$0
Operating Expenses
$12.7K
Cost & Expenses
$12.7K
OPERATING INCOME
-$12.7K
Interest Income
$0
Interest Expense
$0
Other Income/Expenses
$0
INCOME BEFORE TAX
-$12.7K
Income Tax Expense
$0
Net Income from Continuing Ops
-$12.7K
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$12.7K
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$12.7K
D&A
$0
EBIT
-$12.7K
EBITDA
-$12.7K
EPS
-$0
EPS Diluted
-$0
marketcaparena.com
← FY 2023
CURX Overview
Q1 2024 →